INTRODUCTION
Low value pediatric products have traditionally dominated the vaccine field and success has been largely reliant on the recommendations of health
authorities and governments, whose buy-in is essential to vaccine profitability. However, during the next ten years, a number of vaccines aimed at
non-traditional vaccine targets are due for launch.
SCOPE OF THE REPORT
- Patient potential for vaccines targeting all key patient groups, including pediatrics, elderly, travelers and the working and school-age
populations
- Assessment of key unmet needs, and overview of factors and considerations for vaccine clinical trial design
- Overview of the 2003 vaccine pipeline, with detailed analyses of all Phase III vaccines and assessments of market value at maturity
REPORT HIGHLIGHTS
The variety of corporate involvement and the number of products in late-stage vaccine development presents a significant opportunity for key
players to expand their portfolios. Rising competition for a limited number of alliances with larger players could force small biotechnology companies
to fund their own Phase III.
As consumer-led, higher value markets evolve, vaccine positioning will become more critical to product success.
Companies will need to become more effective at targeting non-traditional patient groups if maximum market growth is to be achieved.
Increasing
competition to supply vaccines against specific disease targets will highlight the need for greater product differentiation. Investigating and
incorporating novel formulations, adjuvants and delivery systems could help to maintain competitive advantage.
KEY REASONS TO BUY THIS REPORT
- Evaluate the relative potential of various target patient groups, based on an understanding of the opportunities and challenges presented
- Understand the challenges faced by companies developing vaccines targeting non-traditional diseases and patient groups
View Cart
